Royalty Report: Chemicals, Drugs, Personal Care Products – Collection: 5793

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 7

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7

Primary Industries

  • Chemicals
  • Drugs
  • Personal Care Products
  • Pharmaceuticals
  • Energy & Environment
  • Environmental Control
  • Water Treatment
  • Wound Care

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5793

License Grant
The Licensee has a Royalty Agreement for the Axen product line. The Licensor is the inventor of Axen. The Licensee manufactures and markets the non-toxic, disinfectant product Axen (formerly Microsafe).
License Property
AXEN is a non-toxic, environmentally friendly liquid disinfectant, formulated for initial use as a surface cleaner.  AXEN is also produced with proprietary ionization technology.

AXEN uses ionization stabilization technology to create a liquid disinfectant suitable for many applications, including prevention of contamination by bacteria and viruses. The product is formulated by generating silver ions in a citrate bath, which acts as a stabilizer for the silver.

Field of Use
AXEN can be produced in a liquid concentrated form and used on surfaces in food processing plants, homes, hospitals, restaurants and public facilities to kill bacteria, viruses, and other microorganisms.

Axen formulations have been developed for five separate market groups (1) veterinary medicine, (2) healthcare, including dental applications, (3) drinking water, (4) cooling towers, and (5) as a hard surface disinfectant.  Axen uses ionization stabilization technology to create a liquid disinfectant suitable for many applications, including prevention of contamination by bacteria and viruses. The product is formulated by generating silver ions in a citrate bath, which acts as a stabilizer for the silver. Axen can be produced in a liquid concentrated form and used on surfaces in food processing plants, homes, hospitals, restaurants and public facilities to kill bacteria, viruses, and other microorganisms.

IPSCIO Record ID: 5791

License Grant
The Licensee has also entered an Agreement to manufacture and distribute Axen in the Southeastern United States, Costa Rica, and the Pacific Basin.
License Property
Axen uses ionization stabilization technology to create a liquid disinfectant suitable for many applications, including prevention of contamination by bacteria and viruses.

The product is formulated by generating silver ions in a citrate bath, which acts as a stabilizer for the silver. Axen can be produced in a liquid concentrated form and used on surfaces in food processing plants, homes, hospitals, restaurants and public facilities to kill bacteria, viruses, and other microorganisms.

IPSCIO Record ID: 5794

License Grant
Licensor grants to the Licensee a three year, license to market and distribute Axenohl for the described markets where geographic exclusivity is detailed. Exclusivity is Market specific.

Licensor holds all rights to the product known Axenohl, being patented pending products for the killing of bacterial and other biological contaminants from a water system and Licensor desires to license certain marketing and distribution rights to the Licensed Products to the Licensee on the terms and conditions set forth herein.

License Property
The product is formulated by generating silver ions in a citrate bath, which acts as a stabilizer for the silver. Axen can be produced in a liquid concentrated form and used on surfaces in food processing plants, homes, hospitals, restaurants and public facilities to kill bacteria, viruses, and other microorganisms.

Axenohl is a non-toxic antimicrobial technology that incorporates the biocidal properties of stabilized ionic silver to kill bacteria, viruses and fungi. Axenohl does not include the use of traditional disinfectants such as quaternary ammonium salts, phenols, glutaraldehyde, chlorine or bromine compounds.  The disinfection efficacy of Axenohl has been well documented by independent testing laboratories. Axenohl eliminates the following test organism strains all within one minute and 99.9999% efficacy.

IPSCIO Record ID: 28219

License Grant
The Company grants to the Manufacturer the right and license to use the Intellectual Property solely for the purposes of manufacturing, having manufactured, marketing, and selling Products directly to end-users in the Manufacturer Exclusive Territory.
License Property
AXEN is a non-toxic, environmentally friendly liquid disinfectant, formulated for initial use as a surface cleaner.

The agreement references the AXEN Product line and there are non-compete restrictions included preventing the parties to own or hold any ownership interest in any person or entity engaged in research, manufacturing, or marketing a produce similar in composition and method of production to the product AXEN, in its various formulations in any state or country.

Field of Use
Use Dilutions means any dilutions of AXEN concentrates by any means in which the dilution and repackaging thereof results in increased value of the Product.

IPSCIO Record ID: 27813

License Grant
The Licensor entered into an Agreement for the development and commercialization of certain FDA regulated silver dihydrogen citrate based products (SDC).
License Property
The amended and expanded joint development initiative is to include the development of SDC as an active pharmaceutical ingredient in products for the treatment of dermatophytoses such as Tinea pedis (athlete’s foot), onychomycosis (nail fungus), as well as the development of antimicrobial skin wash products, beginning with a hand sanitizer. Our SDC technology also shows promise as a broad-spectrum antimicrobial for multiple other medical indications, including wound and burn care, as well as for dental and veterinary indications, though these opportunities are not currently under active development.

The Licensor's flagship bioscience technology is an aqueous disinfectant, silver dihydrogen citrate. A patented new molecule, SDC is an electrolytically generated source of stabilized ionic silver that can serve as the basis for a broad range of products in diverse markets. SDC liquid is colorless, odorless, tasteless, non-caustic and formulates well with other compounds. As a platform technology, our SDC-based antimicrobial is distinguished from competitors in the marketplace because of its superior efficacy combined with reduced toxicity. We produce and market pre-formulated, ready-to-use products, as well as varying strengths of SDC concentrate as an additive or raw material for inclusion in other companies’ products.

Field of Use
The field of use relates to broad-spectrum antimicrobial and anti-fungal for use in human and veterinary healthcare industry.

IPSCIO Record ID: 5792

License Grant
The Licensor, an United Kingdom company, hereby grants a non-exclusive license to the Licensee to manufacture and sell the product for a period of five years from the date hereof.  Random Metering System. Traditional ionization equipment produces the same output rate of ions, regardless of the demands placed on the water system.
License Property
The Random Metering System expands the application of ionization disinfection systems by creating a separate water source to create ions outside of the treated water stream. RMS is the only known ionization water disinfection system which can treat large volumes of drinking water. By controlling the off-line water flow, ions can be concentrated and injected into the treated water based on actual demand and flow rates. Ions produced by the RMS product do not dissipate in high temperatures. This characteristic enables RMS products to be used specifically to prevent and control Legionella. The Legionella organism thrives within colonies of microorganisms, which adhere to the inside of piping distribution networks that transport water for domestic and drinking water use. Because RMS can treat even large volumes of water effectively, it can be used in health care and hospital.
Field of Use
Territory global markets vie the Licensee's existing direct sales force and authorised agents and affiliates in the following areas Hot and Cold water systems, cooling towers, drinking water, w4mminp pools, sees, ho; baths, ornamental water, golf courses, horticulture, animal husbandry, irrigation water, hydroponics. NFT effluent treatment, processing plant disinfection, saline water and sea water.

IPSCIO Record ID: 5888

License Grant
Licensor from England hereby grants to Licensee a license to use the Manufacturing Know-How, and the Technical Know-How to enable it to assemble, sell, distribute and service the RMS System and the Products in the Territories during the term of this Agreement.
License Property
Patent Applications together means (a) the pending application for a patent for electronic water treatment products incorporating the Random Metering System (RMS).

The Random Metering System (RMS) expands the application of ionization disinfection systems by creating a separate water source to create ions outside of the treated water stream. RMS is the only known ionization water disinfection system which can treat large volumes of drinking water. By controlling the off-line water flow, ions can be concentrated and injected into the treated water based on actual demand and flow rates.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.